General Information of This Metabolic Reaction (MR) (ID: MR013626)
Formula
Reactant T-2513 Product SN-38
Reactant Info Product Info
Metabolic Enzyme Carboxylesterase 1 (CES1) DME Info
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR013625 T-0128 T-2513 Unclear T-0128 [1]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR013628 T-2513 T-0055 Unclear T-0128 [1]
MR013629 T-2513 T-1335 Unclear T-0128 [1]
MR013630 T-2513 T-3921 Unclear T-0128 [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001226 Irinotecan hydrochloride SN-38 Unclear Irinotecan hydrochloride [2], [3], [4]
MR013226 Sacituzumab govitecan SN-38 Other reaction - Cleavage Sacituzumab govitecan [5]
MR005887 SN-38G SN-38 Unclear SN-38G [6]
MR012144 Irinotecan SN-38 Unclear - Unclear Etirinotecan pegol [7]
References
1 Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors
2 Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients Drug Metab Dispos. 2000 Apr;28(4):423-33.
3 Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model. Br J Pharmacol. 2023 May;180(10):1362-1378. doi: 10.1111/bph.16020.
4 UHPLC-MS/MS method for the quantification of ultra-traces of irinotecan and its metabolites in red blood cells and plasma to detect caregivers' contamination. Drug Test Anal. 2023 Jun 28. doi: 10.1002/dta.3539.
5 Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
6 The gut microbiome: an orchestrator of xenobiotic metabolism
7 Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.